Designing a HER2/neu promoter to drive α1,3galactosyltransferase expression for targeted anti-αGal antibody-mediated tumor cell killing

INTRODUCTION: Our goal was to specifically render tumor cells susceptible to natural cytolytic anti-αGal antibodies by using a murine α1,3galactosyltransferase (mαGalT) transgene driven by a designed form of HER2/neu promoter (pNeu), the transcription of which is frequently observed to be above basa...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanteri, Marion, Ollier, Laurence, Giordanengo, Valérie, Lefebvre, Jean-Claude
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2005
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175063/
https://www.ncbi.nlm.nih.gov/pubmed/15987454
http://dx.doi.org/10.1186/bcr1034

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1175063/
https://www.ncbi.nlm.nih.gov/pubmed/15987454
http://dx.doi.org/10.1186/bcr1034

Ejemplares similares